Therapeutic Drug Monitoring of Aminoglycosides and Vancomycin: Guidelines and Controversies

Abstract

Get full access to this article

View all access options for this article.

References

Vozeh S. : Cost-effectiveness of therapeutic drug monitoring. Clin Pharmacokinet 13:131-140, 1987

Rodvold KA , Zokufa H. , Rotschafer JC : Aminoglycoside pharmacokinetic monitoring: An integral part of patient care? Clin Pharm 7:608-613, 1988

Edwards DJ , Pancorbo S. : Routine monitoring of serum vancomycin concentrations: Waiting for proof of its value. Clin Pharm 6:652-654, 1987

Rodvold KA , Zokufa H. , Rotschafer JC : Routine monitoring of serum vancomycin concentrations: Can waiting be justified? Clin Pharm 6:655-658, 1987

Zaske DE : Aminoglycosides, in Evans WE , Schentag JJ , Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring (ed 2). Spokane, WA, Applied Therapeutics, 1986, pp 331-381

Zaske DE , Cipolle RJ , Strate RJ : Gentamicin dosage requirements: Wide interpatient variations in 242 surgery patients with normal renal function. Surgery 87:164-169, 1980

Deeter RG , Krauss EA , Penn F. , et al: Comparison of aminoglycoside clearance and calculated serum creatinine clearances. Ther Drug Monit 11:155-161, 1989

Lesar TS , Rotschafer JC , Strand LM , et al: Gentamicin dosing errors with four commonly used nomograms. JAMA 248:1190-1193,1982

Healy DP , Polk RE , Garson ML , et al: Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 31:393-397, 1987

10.

Rotschafer JC , Crossley K. , Zaske DE , et al: Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 22:391-394,1982

11.

Birt JK , Chandler Mhh : Using clinical data to determine vancomycin dosing parameters. Ther Drug Monit 12:206-209,1990

12.

Matzke GR , Kovarik JM , Rybak MJ , et al. Evaluation of the vancomycin-clearance: Creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm 4:311-315,1985

13.

Zokufa HZ , Rodvold KA , Blum RA , et al: Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients. Pharmacotherapy 9:10-16, 1989

14.

Matzke GR , McGory RW , Halstenson CE , et al: Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433-437,1984

15.

Cutler NR , Narang PK , Lesko LJ , et al: Vancomycin disposition: The importance of age. Clin Pharmacol Ther 36:803-810,1984

16.

Blouin RA , Bauer LA , Miller DD , et al: Vancomycin pharmacokinetics in normal and morbidly obese subjects . Antimicrob Agents Chemother 21:575-580, 1982

17.

Rybak MJ , Albrecht LM , Warbasse LH , et al: Vancomycin protein binding in a patient population. Pharmacotherapy 182:189, 1989 (abstr)

18.

Rodvold KA , Blum RA , Fischer JH , et al: Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 32:848-852, 1988

19.

Moore RD , Smith CR , Lietman PS : The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 149:443-448, 1984

20.

Moore RD , Smith CR , Lieiman PS : Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 77:657-662, 1984

21.

Zaske DE , Bootman JL , Solem LB , et al: Increased burn patient survival with individualized dosages of gentamicin. Surgery 91:142-149, 1982

22.

Gill MA , Cheetham TC , Chenella FC , et al: Matched case-control study of adjusted versus nonadjusted gentamicin dosing in perforated and gangrenous appendicitis. Ther Drug Monit 8:451-456,1986

23.

Moore RD , Smith CR , Lietman PS : Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 149:23-30, 1984

24.

Cimino MA , Rotstein C. , Slaughter RL , et al: Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy . Am J Med 83:1091-1097,1987

25.

Moore RD , Smith CR , Lipshy JJ , et al: Risk factors for nephrotoxicity in patients treated with aminoglycosides . Ann Intern Med 100:352-357, 1984

26.

Sawyers CL , Moore RD , Lerner SA , et al: A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 153:1062-1068, 1986

27.

Verpooten GA , Giuliano RA , Verbist L. , et al: Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 45:22-27, 1989 28. Gibson GA , Lawson LA , Miller DE , et al: Pharmacokinetic monitoring decreases the risk of gentamicin nephrotoxicity. Clin Pharmacol Ther 45:157, 1989 (abstr)

28.

Sorrell TC , Packham DR , Shanker S. , et al: Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 97:344-350,1982

29.

Schaad UB , McCracken GH , Nelson JD : Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 96:119-126,1980

30.

Lisby-Sutch SM , Nahata MC : Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 35:637-642, 1988

31.

Farber BF , Moellering RC : Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23:138-141, 1983

32.

Rybak MJ , Albrecht LM , Boike SC , et al: Nephrotoxicity of vancomycin, alone and with an aminoglycoside . J Antimicrob Chemother 25:679-687, 1990

33.

Marre R. , Schulz E. , Anders T. , et al: Renal tolerance and pharmacokinetics of vancomycin in rats.1 J Antimicrob Chemother 14:253-260, 1984

34.

Rybak MJ , Frankowski JJ , Edwards DJ , et al: Alanine aminopeptidase and B2-microglobulin excretion in patients receiving vancomycin and gentamicin. Antimicrob Agents Chemother 31:1461-1464, 1987

35.

Wood CA , Kohihepp SJ , Kohnen PW , et al: Vancomycin enhancement of experimental tobramycin nephrotoxicity . Antimicrob Agents Chemother 30:20-24, 1986

36.

Franson TR , Quebbeman EJ , Whipple J. , et al: Prospective comparison of traditional and pharmacokinetics aminoglycoside dosing methods. Crit Care Med 16:840-843, 1988

37.

Hickling K. , Begg E. , Moore ML : A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosideswith prediction based on estimated creatinine clearance in critically ill patients. Intensive Care Med 15:233-237, 1989

38.

Reed RL , Wu AH , Miller-Crotchett P. , et al: Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma 29:1462-1470, 1989

39.

Perkins MW : Failure of a nomogram to achieve target aminoglycoside concentrations. Br J Clin Pharmacol 29:495-496, 1990

40.

Hull JH , Sarubbi FA : Gentamicin serum concentrations: Pharmacokinetic predictions. Ann Intern Med 85:183-189,1976

41.

Moellering RC , Krogstad DJ , Greenblatt DJ : Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Ann Intern Med 94:343-346, 1981

42.

Lake KD , Peterson CD : A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 5:340-344, 1985

43.

Rybak MJ , Boike SC : Individualized adjustment of vancomycin dosage: Comparison with two dosage nomograms. Drug Intell Clin Pharm 20:64-68, 1986

44.

Lake KD , Peterson CD : Evaluation of a method for initiating vancomycin therapy: Experience in 205 patients. Pharmacotherapy 8:284-286, 1988

45.

Eisenberg JM , Koffer H. , Glick HA , et al: What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 107:900-909, 1987

46.

Garrison MW , Zaske DE , Rotschafer JC : Aminoglycosides: Another perspective. DICP 24:267-272, 1990

47.

Crist KD , Nahata MC , Ety J. : Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit 9:306-310, 1987

48.

Burton ME , Chow Mss , Platt DR , et al: Accuracy of Bayesian and Sawchuk-Zaske dosing methods for gentamicin . Clin Pharm 5:143-149,1986

49.

Rodvold KA , Blum RS : Predictive performance of Sawchuk Zaske and Bayesian dosing methods for tobramycin . J Clin Pharmacol 27:419-424,1987

50.

Rodvold KA , Pryka RD , Garrison M. , et al: Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther Drug Monit 11:269-275,1989

51.

Anderson AC , Hodges GR , Barnes WG : Determination of serum gentamicin sulfate levels: Ordering patterns and use as a guide to therapy. Arch Intern Med 136:785-787, 1976

52.

Slaughter RL : Probability assessment approach to therapeutic drug monitoring: Tobramycin. DICP 23:240-244, 1989

53.

Destache CJ , Meyer SK , Bittner MJ , et al: Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: A cost-benefit analysis . Ther Drug Monit 12:419-426, 1990

54.

Chan Glc : Alternative dosing strategy for aminoglycosides: Impact on efficacy, nephrotoxicity and ototoxicity. DICP 23:788-794,1989

55.

Sattler FR , Cowan R. , Nielsen DM , Ruskin J. : TMP/ SMX compared with pentamidine for treatment of PCP in the acquired immunodeficiency syndrome. Ann Intern Med 109:280-287, 1988

56.

Moore RD , Lietman PS , Smith CR : Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93-99, 1987